Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Parkinson Disease 4, Autosomal Dominant Lewy Body 25Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 20Melanoma 19Neoplasm Metastasis 18Neoplasms 16Endometrial Neoplasms 14Colorectal Neoplasms 14Breast Neoplasms 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 11Head and Neck Neoplasms 9Carcinoma, Renal Cell 8Pancreatic Neoplasms 7Carcinoma, Transitional Cell 7Urinary Bladder Neoplasms 6Recurrence 5Lymphoma 5Hodgkin Disease 5Esophageal Neoplasms 4Carcinoma 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Prostatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Jaw Neoplasms × pembrolizumab × 30 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡